New York, NY -- (ReleaseWire) -- 04/19/2013 --Roche Holding AG (OTC:RHHBY) and Isis Pharmaceuticals, Inc. (ISIS) announced, earlier this month, that they have formed an alliance to develop treatments for Huntington's disease (HD) based on Isis' antisense oligonucleotide (ASO) technology.

Under the terms of the agreement, Roche will make an upfront payment of $30 million to Isis, with total payments related to license fee and pre- and post-licensing milestone payments reaching potentially $362 million, including up to $80 million in potential commercial milestone payments. In addition, Isis will receive tiered royalties on sales of the drugs. Roche has the option to license the drugs from Isis through the completion of the first Phase 1 trial.

Roche Holding AG operates in the fields of pharmaceuticals and diagnostics worldwide.

Find out what could be next for RHHBY by getting the free and complete trend analysis report here: http://www.wallstreetreport.net/market-scan/?symbol=RHHBY

The Wall Street Journal reported that Nestle SA (Pink:NSRGY) Thursday reported its weakest sales performance in more than three years as a dramatic slowdown in the Swiss food giant's previously strong emerging markets business was compounded by continuing weakness in Europe and the Americas.

The maker of Kit-Kat chocolate bars and Nescafe instant coffee said its sales grew 5.4% to 21.94 billion Swiss francs ($23.52 billion) in the three months to March 31 from a restated 20.82 billion francs a year earlier, short of expectations and down from the 10% growth over the course of 2012.

Nestlé S.A., together with its subsidiaries, provides nutrition, health, and wellness products worldwide.

Find out more on NSRGY here:
http://www.wallstreetreport.net/market-scan/?symbol=NSRGY

About WallStreetReport.net
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.WallStreetReport.net

Disclosure
WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.

BlueLys, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit: http://www.wallstreetreport.net/disclaimer-2/

Contact Info:
Michael Baine
WALL STREET REPORT
info@WallStreetReport.net
347-905-5009